Patents by Inventor Daniel Rixson

Daniel Rixson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID STATE FORMS OF MNK INHIBITORS
    Publication number: 20260217712
    Abstract: The present disclosure relates to solid forms of a compound having the following Structure (I): or a tautomer thereof. The present disclosure is also directed to methods of making and using a compound of Structure (I).
    Type: Application
    Filed: January 3, 2024
    Publication date: July 30, 2026
    Inventors: Theodore J. Price, James J. Sahn, Daniel Rixson, Osama Suleiman, Arlindo Lucas Castelhano, Garry Robert Smith
  • PHARMACEUTICALLY ACCEPTABLE 5-METHOXY-N,N-DIMETHYLTRYPTAMINE SALTS AND COMPOSITIONS THEREOF
    Publication number: 20260209175
    Abstract: This invention relates to pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine. In particular, though not exclusively, the invention relates to compositions/formulations and uses of the same as a medicament.
    Type: Application
    Filed: August 21, 2023
    Publication date: July 23, 2026
    Inventors: Jason GRAY, Susana DEL RIO GANCEDO, Daniel RIXSON, Dita DAVIS, David James PEARSON
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF
    Publication number: 20260062383
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Application
    Filed: September 5, 2025
    Publication date: March 5, 2026
    Inventors: David E. NICHOLS, Graham JOHNSON, Hooshang S. ZAVAREH, Claire WOMBWELL, Daniel RIXSON, Peter HADDOW, Carrie SHEARD, Alexander SCHWARZ
  • Pharmaceutically acceptable salts of psilocin and uses thereof
    Patent number: 12545642
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Grant
    Filed: May 3, 2023
    Date of Patent: February 10, 2026
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
  • PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS THEREOF
    Publication number: 20250263372
    Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
    Type: Application
    Filed: February 21, 2025
    Publication date: August 21, 2025
    Inventors: Jason GRAY, Susana DEL RIO GANCEDO, Dita DAVIS, David James PEARSON, Daniel RIXSON
  • Pharmaceutically acceptable salts and compositions thereof
    Patent number: 12264131
    Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: April 1, 2025
    Assignee: Beckley Psytech Limited
    Inventors: Jason Gray, Susana Del Rio Gancedo, Dita Davis, David James Pearson, Daniel Rixson
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF
    Publication number: 20240124398
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Application
    Filed: February 10, 2022
    Publication date: April 18, 2024
    Inventors: David E. NICHOLS, Graham JOHNSON, Hooshang S. ZAVAREH, Claire WOMBWELL, Daniel RIXSON, Peter HADDOW, Carrie SHEARD, Alexander SCHWARZ
  • PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS THEREOF
    Publication number: 20240101514
    Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
    Type: Application
    Filed: August 4, 2023
    Publication date: March 28, 2024
    Applicant: BECKLEY PSYTECH LIMITED
    Inventors: Jason GRAY, Susana DEL RIO GANCEDO, Dita DAVIS, David James PEARSON, Daniel RIXSON
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF
    Publication number: 20230357144
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Application
    Filed: May 3, 2023
    Publication date: November 9, 2023
    Inventors: David E. NICHOLS, Graham JOHNSON, Hooshang S. ZAVAREH, Claire WOMBWELL, Daniel RIXSON, Peter HADDOW, Carrie SHEARD, Alexander SCHWARZ
  • Pharmaceutically acceptable salts and compositions thereof
    Patent number: 11773063
    Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: October 3, 2023
    Assignee: Beckley Psytech Limited
    Inventors: Jason Gray, Susana Del Rio Gancedo, Dita Davis, David James Pearson, Daniel Rixson
  • Pharmaceutically acceptable salts of psilocin and uses thereof
    Patent number: 11680043
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: June 20, 2023
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
  • PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF
    Publication number: 20220289676
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Application
    Filed: March 30, 2022
    Publication date: September 15, 2022
    Inventors: David E. NICHOLS, Graham JOHNSON, Hooshang S. ZAVAREH, Claire WOMBWELL, Daniel RIXSON, Peter HADDOW, Carrie SHEARD, Alexander SCHWARZ
  • Pharmaceutically acceptable salts of psilocin and uses thereof
    Patent number: 11312684
    Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: April 26, 2022
    Assignee: Eleusis Therapeutics US, Inc.
    Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz